Find policies, billing codes, payers, states, and providers
Microwave Thermotherapy
Customize your policy alerts
Sign up for Aetna Policy 0682 alerts
Get alerted when Policy 0682 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's coverage stance for microwave thermotherapy (focused microwave thermotherapy/phase array thermotherapy) across multiple indications and lists related policies and coding references; affects providers requesting coverage for these therapies.
No material clinical or coverage changes in this revision.
Coverage Criteria
Experimental and Investigational
Aetna considers microwave thermotherapy experimental and investigational for the following indications because of insufficient evidence of effectiveness:
List not all-inclusive.
Potential appropriate uses (based on available evidence)
Considered when ALL of the following supporting elements are documented:
See imaging/follow-up schedules in documentation module
Data are primarily from single-center retrospective series, systematic reviews of small non-comparative studies, and Level III evidence
Not supported / insufficient evidence
Considered NOT supported when any of the following apply:
Absence in guideline documents cited in the policy
RCT evidence reported in policy shows no added benefit
MW therapy shown inferior or less favorable versus FU in meta-analysis
Study eligibility examples
Reported study eligibility and selection criteria (examples):
From retrospective limb‑salvage series (Han et al. and Li et al.)
From Gao et al. retrospective study
From Deib et al. retrospective review
Aetna classifies microwave thermotherapy (also referred to as focused microwave thermotherapy or focused microwave phased‑array thermotherapy) as experimental and investigational for a range of listed indications because the available evidence is insufficient to demonstrate effectiveness for these uses. Examples of indications designated experimental/investigational include bladder cancer; bone cancer/limb salvage; breast cancer and breast metastases; cervical ectopy; chronic low back pain; chronic neck pain; chronic pelvic pain syndrome; chronic prostatitis; dysmenorrhea; keratoconus; kidney cancer; lung cancer; nasopharyngeal cancer; osteosarcoma; pancreatic cancer; and rheumatoid arthritis.
Several indications named in the policy are not supported or are not mentioned in major practice guidelines cited in the document. For example, the 2013 European Association of Urology update and the NCCN bladder cancer guideline (Version 2.2015) do not list microwave thermotherapy as a therapeutic option, and the policy also notes guideline absence for several other tumor types; this absence of guideline endorsement was a factor in classifying those indications as investigational.
Study-based limb‑salvage use of intraoperative microwave hyperthermia has patient selection limits and contraindications reported in the literature. Eligibility in cited series included an available tumor‑to‑articular distance (for example, ≥ 20 mm from the tumor edge to the articular surface in study cohorts), good clinical and imaging response to neoadjuvant chemotherapy, absence of pathologic fracture, and salvageable major arteries. Patients who lacked adequate distance to the joint surface, had poor response to neoadjuvant therapy, pathologic fracture, or unsalvageable vascular anatomy were treated with amputation and were excluded from hyperthermia in the reports.
The policy does not frame these procedures using the explicit phrase 'not medically necessary' in the experimental and investigational coverage section; instead, it classifies microwave thermotherapy as experimental and investigational for the listed indications and states that these indications are therefore excluded from coverage based on insufficient evidence of effectiveness.
Randomized controlled trials of microwave diathermy for chronic low back pain and chronic neck pain did not demonstrate added clinical benefit over exercise programs or sham/unplugged treatments. Because RCT evidence failed to show superiority of microwave diathermy compared with standard conservative therapy, use of microwave diathermy for these chronic non‑oncologic pain indications is not supported by the evidence cited in the policy.
The policy notes that the National Comprehensive Cancer Network’s kidney cancer guideline (Version 2.2017) does not mention microwave thermotherapy as a treatment option. The absence of this modality from the NCCN guideline is cited as evidence that microwave thermotherapy is not an established therapeutic option for kidney cancer in guideline recommendations.
Coding and Billing
| C9751 | Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s). |
| 77280-77295 | Radiation therapy. |
| C11.0-C11.9 | Malignant neoplasm of nasopharynx |
| C25.0-C25.9 | Malignant neoplasm of pancreas |
| C33-C34.92 | Malignant neoplasm of trachea, bronchus and lung |
| C40.00-C41.9 | Malignant neoplasm of bone and articular cartilage of limbs |
| C64.1-C64.9 | Malignant neoplasm of kidney, except renal pelvis |
| C67.0-C67.9 | Malignant neoplasm of bladder |
| C50.011-C50.929 | Malignant neoplasm of breast |
| C79.81 | Secondary malignant neoplasm of breast |
| D05.00-D05.92 | Carcinoma in situ of breast |
| H18.601-H18.629 | Keratoconus |
| No codes listed |
Provider Actions and Authorization Guidance
Prior authorization: tumor characteristics and intent
Prior authorization may be required for microwave thermotherapy procedures depending on the service code and the member’s plan. When requesting prior authorization, document tumor characteristics (size, location, number of lesions) and the clinical intent of the procedure (curative, palliative, limb-sparing, pain control, or other intent). Provide prior-authorization reviewers with tumor measurements, imaging reports, and a statement of treatment intent to support clinical review.
- Document tumor size, location, number of lesions, and clinical intent on the prior authorization request.
- Confirm whether specific CPT/HCPCS codes referenced in the policy require prior authorization under the member’s benefit plan.
Prior authorization
Prior authorization: confirm requirements with the payer and include supporting clinical documentation. If uncertain about whether a given CPT/HCPCS code for microwave procedures is covered, contact Aetna’s provider services or use the plan’s authorization portal to verify coverage and obtain any required approvals prior to scheduling.
- Include relevant ICD-10 diagnosis codes when requesting authorization.
- If applicable, attach prior imaging, pathology, and prior treatment history (e.g., prior chemotherapy, radiation, BCG) to the authorization submission.
Denial risk for experimental/investigational indications
Procedures and indications listed in this policy (for example: bladder cancer, bone cancer/limb salvage, chronic low back/neck pain, kidney cancer, osteosarcoma, and others) are considered experimental and investigational by Aetna for the listed indications and therefore are at high risk for denial when requested for these purposes.
- Expect denial risk for microwave thermotherapy when used to treat indications listed as experimental/investigational (see policy list).
- If proposing use outside listed indications, provide high-quality evidence and rationale; anticipate case-by-case medical review.
Guideline absence may trigger review
Absence of microwave thermotherapy from major guideline statements (e.g., EAU, NCCN) may prompt additional review or denial. Provide evidence-based justification if requesting coverage for indications not supported by these guidelines.
- When guidelines do not mention the therapy, include peer-reviewed studies, systematic reviews, or RCT data to justify medical necessity.
- For bladder cancer (NMIBC) consider including details on sequencing relative to BCG and other standard therapies.
No explicit authorization or denial triggers in policy text
The policy text does not specify explicit authorization or denial triggers (e.g., no numeric tumor-size cutoffs or mandated prior therapy sequences are listed). Authorization decisions will therefore be based on submitted clinical documentation and medical review.
- Because explicit triggers are not provided, ensure completeness of records: imaging, pathology, prior treatments, and rationale for selecting microwave therapy.
- Authorization outcomes are determined by clinical review; absence of detailed policy thresholds does not imply routine approval.
No documentation requirements specified in these chunks
No additional or alternative documentation requirements are specified in the provided policy chunks beyond standard prior-authorization submissions and clinical records. Follow payer-specific submission instructions and contact the plan for any additional required forms.
- If plan-specific documentation rules exist (not included here), follow those instructions.
- When in doubt, submit comprehensive clinical records to support medical necessity.
Coding and diagnosis documentation
When billing, include appropriate CPT/HCPCS and ICD-10 codes and document the diagnoses that justify the procedure. The policy contains lists of CPT/HCPCS/ICD-10 codes relevant to microwave thermotherapy—ensure claims include the correct diagnosis pointers and any required modifiers.
- Attach imaging and operative reports that corroborate the diagnosis codes on the claim.
- Verify each CPT/HCPCS used is appropriate for the billed indication and supported by documentation.
Required clinical documentation
Required clinical documentation to support authorization/medical review includes pre-procedure imaging, peri-procedural and immediate post-procedure imaging (when applicable), and follow-up imaging schedules. For example studies referenced in the policy used imaging at pre-ablation and at 1 day, 1 month, 3 months, then every 6 months post-ablation to document initial ablation success and ongoing control.
- Provide imaging reports (CT/MR/CEUS) demonstrating tumor size and location pre-procedure.
- Include post-procedure imaging and planned surveillance schedule to document treatment response.
Therapeutic sequencing considerations for NMIBC
Therapeutic sequencing: for non–muscle-invasive bladder cancer (NMIBC), chemo-hyperthermia (microwave-induced hyperthermia combined with intravesical chemotherapy) has been studied as an adjunct to intravesical chemotherapy and in settings where BCG is contraindicated or when patients are unsuitable for cystectomy. Document prior intravesical treatments (e.g., MMC, BCG), tumor recurrence history, and reason for selecting chemo-hyperthermia.
- Indicate whether chemo-hyperthermia is being used as first-line adjuvant therapy, salvage therapy after BCG failure, or for BCG-contraindicated patients.
- Provide recurrence history, prior treatment dates, and response to prior therapies.
Non-oncologic conservative therapy precedence
For non-oncologic indications such as chronic low back or neck pain, randomized trials cited in the policy found no added benefit of therapeutic microwave diathermy over exercise and education. Prioritize conservative therapies (exercise programs, education) before considering microwave approaches for these conditions and document prior conservative therapy attempts.
- Document prior conservative treatments (physical therapy, exercise programs, medications) and their outcomes when requesting coverage for pain-related indications.
- Note that RCT evidence did not demonstrate superiority of microwave diathermy compared with exercise/education.
Background and Evidence Summary
Microwave thermotherapy uses electromagnetic microwaves to raise local tissue temperature and has been investigated both as an ablative technique (microwave ablation) and as an adjunctive or hyperthermia treatment across a range of malignant and non‑malignant conditions. The clinical evidence summarized in the policy is largely comprised of pilot studies, retrospective series and some phase II work; for most listed indications there is insufficient high‑quality comparative evidence to establish effectiveness, and therefore these applications are considered experimental and investigational.
Definitions
Revision History
Policy last reviewed on 2023-09-19.
Policy originally became effective on 2004-02-17.
Next scheduled policy review date is 2024-07-25.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.